SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025
Paris, 9 October 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces the presentation of data on its two gene-agnostic gene therapy programs, SPVN06 and SPVN20, and related research, at the 32nd Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT), held from 7-10 October 2025, in Seville, Spain.
Hanen Khabou, Ph.D., Senior Scientist at SparingVision, presented preclinical data demonstrating the potential of SPVN20 to restore vision in late-stage RP patients with dormant cones, independently of the causative genetic mutation. Studies in murine models showed restoration of cone-driven responses, while nonclinical data in non-human primates confirmed robust, targeted transgene expression in the fovea and a favorable safety profile following a single intravitreal administration of SPVN20. The non-clinical data package presented at ESGCT supported the company’s Clinical Trial Application (CTA) for a first-in-human trial of SPVN20 in RP, which has now been authorized in France, Belgium, and Ireland.
In addition, Laure Blouin, Director, Clinical Science and Medical Communications, presented positive Phase I safety data from PRODYGY, the ongoing clinical trial of SPVN06 in patients with advanced RP. Results show that SPVN06 continues to demonstrate a favorable safety profile up to 18 months post-treatment, with no serious adverse events, no dose-limiting toxicities, and no discontinuations. No significant intraocular inflammation or immune response was observed, underscoring the therapy’s long-term tolerability.
In related research, Alice Le Meur, Head of Clinical Operations, shared third-year follow-up data from PHENOROD2, a four-year prospective natural-history study and one of the largest ever conducted in patients with rod-cone dystrophy caused by variants in RHO, PDE6A or PDE6B genes. Preliminary analyses confirm the expected slow annual progression of disease in this population, evaluating various structural and functional parameters such as the horizontal width of the ellipsoid zone, visual field and best-corrected visual acuity (BCVA). Ongoing patient monitoring in PHENOROD2 is generating a valuable clinical dataset that will help inform the design and endpoints of future interventional trials, including those with SPVN06.
**ENDS**
NOTES TO EDITORS
Contacts:
Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)
Media: ICR Healthcare (sparingvision@icrhealthcare.com)
About SparingVision
SparingVision is a clinical-stage genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for blinding retinal diseases. Its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP) and geographic atrophy secondary to dry-AMD, two leading causes of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X @SparingVision